Meet the Newest ALS Pioneer Company from Switzerland

08/12/2016 - 3 minutes

AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist.

The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. Located in Switzerland, AL-S Pharma has the single aim of developing a drug candidate for amyotrophic lateral sclerosis (ALS).

The giant Eli Lilly is also contributing through Chorus, a division directed to advance drug candidates using cost-effective clinical strategies. If everything goes as planned, Chorus will step in in 2018, when the first human study of AL-S’ candidate is projected to begin.

The drug candidate, AP-101, is a human monoclonal antibody that targets misfolded SOD1 proteins that cause ALS. It was generated and validated in pre-clinical models by Neurimmune’s Reverse Translational Medicine platform. This technology uses high-throughput analysis of human immune responses to specific disease-related proteins in order to identify targets for therapeutic antibodies.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!